Tingting Niu, Mi Fan, Binwei Lin, Feng Gao, Bangxian Tan, Xiaobo Du
Radionuclide-based therapy represents a novel treatment regimen for tumors. Among these therapies, lutetium-177 (177 Lu) has gained significant attention due to its stability and safety, as well as its ability to emit both γ and β rays, allowing for both imaging with single photon emission computed tomography and tumor treatment. As a result, 177 Lu can be used for both diagnosis and treatment for diseases such as prostatic and gastric cancer. Therefore, based on the available data, the present review provides a brief overview of the clinical applications of 177 Lu-targeted radionuclide therapy in metastatic prostate cancer, neuroendocrine tumors and other types of solid tumors, and highlights the current therapeutic effect, reduction in damage to normal tissues and future research directions, including the development of new nuclides and the application of more nuclides in different tumors...
May 2024: Experimental and Therapeutic Medicine